Search

Displaying results 6071 - 6080 of 6198 in total
  1. Drug

    SNS-314

    go.drugbank.com/drugs/DB06134
    Investigational

    SNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C. Proliferating cells treated with SNS-314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis, leading to multiple rounds of endoreduplication an...

  2. Drug

    TRC093

    go.drugbank.com/drugs/DB06356
    Investigational

    TRC093 is a recombinant humanized IgG1k monoclonal antibody.

  3. Drug

    Incadronic acid

    go.drugbank.com/drugs/DB06255
    Experimental

    Incadronate, or YM-175, is a nitrogen containing bisphosphonate. Along with being investigated to treat hypercalcemia of malignancy, it has also been investigated in the treatment of myeloma, leukemia, and other cancers. Incadronic acid ...

  4. Drug

    LJP 1082

    go.drugbank.com/drugs/DB05446
    Experimental

    Patients with high levels of anticardiolipin antibodies (ACA) have an increased risk of stroke, heart attack, deep vein thrombosis, and recurrent fetal loss.

  5. Drug

    Chloropyramine

    go.drugbank.com/drugs/DB08800
    Investigational

    Chlorpyramine is a first generation antihistamine used in Eastern European countries to treat bronchial asthma as well as allergice rhinitis, allergic conjunctivitis, and other allergic reactions. It is also indicated for Quincke's edema...

  6. Drug

    XAV-19

    go.drugbank.com/drugs/DB15895
    Investigational

    XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on [COVID-19 convalescent plasma].

  7. Drug

    Etesevimab

    go.drugbank.com/drugs/DB15897
    Investigational

    Etesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain. Under the EUA granted in February 2021, etesevimab is used in com...

  8. Drug

    Abivertinib

    go.drugbank.com/drugs/DB15327
    Investigational

    In binding to and inhibiting EGFR and BTK receptors, abivertinib exerts immunomodulatory effects by preventing the production and release of pro-inflammatory cytokines (e.g. TNF-alpha, interleukins).

  9. Drug

    Abdavomeran

    go.drugbank.com/drugs/DB15695
    Investigational

    [L15017, L15022] BNT162b1 received fast track designation by the FDA on July 13, 2020.[L15027]

  10. Drug

    Contulakin-G

    go.drugbank.com/drugs/DB05950
    Experimental

    Contulakin-G is a broad spectrum non-opioid analgesic. It is the synthetic form of a natural peptide extracted from the venom of the Conus Geographus sea snail.